Research article

# Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

Suvichada Assawakosri<sup>a,b</sup>, Sitthichai Kanokudom<sup>a,b</sup>, Nungruthai Suntronwong<sup>a</sup>, Jira Chansaenroj<sup>a</sup>, Chompoonut Auphimai<sup>a</sup>, Pornjarim Nilyanimit<sup>a</sup>, Preeyaporn Vichaiwattana<sup>a</sup>, Thanunrat Thongmee<sup>a</sup>, Thaneeya Duangchinda<sup>c</sup>, Warangkana Chantima<sup>d,e</sup>, Pattarakul Pakchotanon<sup>c</sup>, Donchida Srimuan<sup>a</sup>, Thaksaporn Thatsanatorn<sup>a</sup>, Sirapa Klinfueng<sup>a</sup>, Natthinee Sudhinaraset<sup>a</sup>, Nasamon Wanlapakorn<sup>a</sup>, Juthathip Mongkolsapaya<sup>f,g</sup>, Sittisak Honsawek<sup>b\*\*</sup>, Yong Poovorawan<sup>a,h\*</sup>

<sup>a</sup> Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand

<sup>b</sup>Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand

<sup>c</sup> Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Development Agency, NSTDA, Pathum Thani 12120, Thailand <sup>d</sup> Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

<sup>e</sup> Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

<sup>f</sup> Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK

<sup>g</sup> Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

<sup>h</sup> FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand

\*Correspondence: Prof. Yong Poovorawan, MD. Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University. Bangkok, 10330 Thailand. E-mail: yong.p@chula.ac.th

\*\*Correspondence: Prof. Sittisak Honsawek, MD. Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand E-mail: sittisak.h@chula.ac.th

Main text: 3327 words

Abstract: 218 words

# Highlights

- The persistence of antibody responses is different among three vaccine platforms.
- Highly remained antibody levels were observed with the mRNA and viral vector booster.
- The half-dose mRNA-1273 can be used interchangeably with the full-dose mRNA-1273.
- The neutralizing activity against BA.5 was lower than wild type and BA.2 subvariant.
- A fourth dose is recommended for individuals who received an inactivated booster.

# 1 Abstract

2 **Objectives:** Several countries have authorized a booster vaccine campaign to combat the spread 3 of COVID-19. Data on persistence of booster vaccine-induced immunity against new Omicron 4 subvariants are still limited. Therefore, our study aimed to determine the serological immune 5 response of COVID-19 booster after CoronaVac-priming. 6 **Methods:** A total of 187 CoronaVac-primed participants were enrolled and received an 7 inactivated (BBIBP), viral vector (AZD1222) or mRNA vaccine (full-/half-dose BNT162B2, 8 full-/half-dose mRNA-1273) as a booster dose. The persistence of humoral immunity both 9 binding and neutralizing antibodies against wild-type and Omicron was determined on day 90-10 120 after booster.

11 **Results:** A waning of total RBD immunoglobulin (Ig) levels, anti-RBD IgG, and neutralizing

12 antibodies against Omicron BA.1, BA.2, and BA.4/5 variants was observed 90–120 days after

13 booster vaccination. Participants who received mRNA-1273 had the highest persistence of the

14 immunogenicity response, followed by BNT162b2, AZD1222, and BBIBP-CorV. The responses

15 between full and half doses of mRNA-1273 were comparable. The percentage reduction of

16 binding antibody ranged from 50% to 75% among all booster vaccine.

Conclusions: The antibody response substantially waned after 90–120 days post-booster dose.
The heterologous mRNA and the viral vector booster demonstrated higher detectable rate of
humoral immune responses against the Omicron variant compared to the inactivated BBIBP
booster. Nevertheless, an additional fourth dose is recommended to maintain immune response
against infection.

# 22 Keywords COVID-19 vaccine; durability; CoronaVac; heterologous booster; neutralizing

# antibody; Omicron.

## 24 **1. Introduction**

25 With the ongoing coronavirus disease 2019 (COVID-19) pandemic, the emerging 26 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is 27 considered more transmissible than other previous variants of concern, including Alpha, Beta, 28 and Delta variants (Kumar et al., 2022). Therefore, vaccination is an essential tool to alleviate the 29 spread of the COVID-19 pandemic. The inactivated virus vaccine platform is one of the most 30 widely used as primary regimen among all COVID-19 vaccines. CoronaVac (Sinovac Biotech 31 Co., Ltd., Beijing, China) is one of a whole inactivated virus COVID-19 vaccines that have been 32 approved for use in more than 56 low- and middle-income countries around the world, including 33 Thailand (COVID-19 tracker, 2022). Nevertheless, several studies have demonstrated that the 34 neutralization of the Omicron variant was highly limited in sera from those who received the 35 primary series of COVID-19 vaccines, for either the mRNA or viral vector or inactivated 36 platforms (Edara et al., 2022, Lu et al., 2022, Muik et al., 2022, Planas et al., 2022). Therefore, 37 the use of third dose COVID-19 vaccines has been recommended by the US Food and Drug 38 Administration to combat the new Omicron variant (Centers for Disease Control and Prevention, 39 2022).

In late December 2021, a mass booster dose vaccination campaign was first
recommended in Thailand by the Ministry of Public Health, especially for adults previously
vaccinated with two doses of CoronaVac. Recently, we reported the results of a third dose
booster study in healthy adults previously primed with two doses of CoronaVac. Our finding
showed that a third heterologous dose elicited a robust immune response against the Omicron
variant (Assawakosri et al., 2022b, Kanokudom et al., 2022b). Moreover, a booster with
BNT162b2 in CoronaVac-primed individuals improved vaccine effectiveness (VE) to 92.7% for

protection against COVID-19 infection in Brazil (Cerqueira-Silva et al., 2022b). A significant
challenge in controlling the COVID-19 pandemic is the waning of vaccine-induced immunity. A
previous COV-boost study reported the decline in immunogenicity three months after the third
dose using viral vector platforms, AZD1222 (AstraZeneca, Oxford, UK) (Liu et al., 2022).
However, it is currently unclear on immunogenicity beyond one month following the third
heterologous dose in CoronaVac-primed individuals as is how rapidly protection from booster
dose wanes over time.

54 Subvariants of the Omicron are continuously emerging during the COVID-19 pandemic. 55 Initially, Omicron variants were categorized into several descendent subvariants, including BA.1, 56 BA.1.1, BA.2, BA.2.2, and BA.3 (Viana et al., 2022; Yamasoba et al., 2022). Subsequently, two 57 new Omicron subvariants that harbor the L452R spike protein mutation have been designated as 58 BA.4 and BA.5 (Tegally et al., 2022). Both BA.4 and BA.5 have identical spike protein 59 sequences (hereafter BA.4/5) (Zhou et al., 2022). A previous study showed that the BA.4/5 60 subvariants are more pathogenic than BA.1 and are highly resistant to BA.1 and BA.2-infected 61 sera (Kimura et al., 2022). Furthermore, BA.4/5 exhibited an 18.3-fold higher infectivity rate 62 than that observed in BA.2 (Zhou et al., 2022). However, there are limited data on BA.4/5 63 immune evasion in third-dose heterologous vaccinated individuals. Therefore, the present study 64 aimed to evaluate the durability of immune protection at three to four months following four 65 different heterologous booster vaccines in adults who completed a two-dose CoronaVac. In 66 addition, we also investigated immunogenicity against the newly emerging Omicron variants 67 BA.2 and BA.4/5 subvariants.

## 68 2. MATERIALS AND METHODS

#### 69 **2.1 Study design and participants**

- 70 The study protocol was described in our previous studies (Assawakosri et al., 2022b,
- 71 Kanokudom et al., 2022b). Briefly, this study was a prospective cohort study of heterologous
- third-dose vaccination. All participants were Thai adults over 18 years of age with no previous or
- 73 current diagnosis of COVID-19 infection and who had received the CoronaVac 2-dose vaccine
- 74 (Sinovac Biotech Co., Ltd., Beijing, China) with the 6±1 months interval period. All participants
- 75 were allocated to receive a booster dose of the COVID-19 vaccine, including BBIBP-CorV,
- 76 AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273 (full- or half-dose). The study flow
- is illustrated in Figure 1. This study was conducted in the Clinical Trial Unit, the Center of
- 78 Excellence in Clinical Virology of Chulalongkorn University, Bangkok, Thailand. The study was
- approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn
- 80 University (IRB numbers 546/64 and 498/65). The study was registered with the Thai Registry of
- 81 Clinical Trials (TCTR 20210910002). Written informed consent was obtained from each
- 82 participant before the enrollment and this cohort study was conducted in accordance with the
- 83 Declaration of Helsinki.

#### 84 2.2 Study vaccine

- 85 The study vaccines were as follows: inactivated: BBIBP-CorV (Sinopharm, Beijing, China),
- 86 viral vector: AZD1222 (AstraZeneca, Oxford, UK), mRNA: 30 μg BNT162b2 (full-dose group)
- 87 and 15 μg (half-dose group) (Pfizer-BioNTech Inc., New York City, NY, USA), mRNA: 100 μg
- 88 mRNA-1273 (full-dose group) (Moderna Inc., Cambridge, MA, USA), and 50 µg mRNA-1273
- 89 (half-dose group).

# 90 **2.3 Sample collection**

91 Peripheral venous blood samples (10–15 mL) were collected on day 28, and 90 to 120 after

92 vaccination. The clot blood tubes were then centrifuged at 2000 rpm for 10 minutes at room

93 temperature to collect serum samples. All specimens were stored at -20°C until further analysis.

## 94 2.4 Total RBD Ig, anti-RBD IgG, and anti-nucleocapsid assay

- 95 Serum samples were used to measure total immunoglobulin (Ig) specific for the RBD of SARS-
- 96 CoV-2 using an electrochemiluminescence immunoassay—Elecsys SARS-CoV-2 S (Roche
- 97 Diagnostics, Basel, Switzerland)—according to the manufacturer's instructions and as previously
- 98 described (Kanokudom et al., 2022). The Ig titer was determined as unit per milliliter (U/mL),
- 99 and the level  $\geq 0.8$  U/mL was considered a positive detection.
- 100 The levels of IgG specific to an RBD and nucleocapsid protein of the SARS-CoV-2 virus in
- 101 serum samples were detected by the chemiluminescence microparticle immunoassay (Abbott,
- 102 Sligo, Ireland). Anti-RBD IgG is a quantitative assay with a limit of detection level at  $\geq 21$
- 103 AU/mL, a lower level of less than 50 AU/mL is considered a negative result. While the Anti-
- 104 nucleocapsid IgG is a semi-quantitative technique, the level  $\geq$  1.4 sample/cutoff (S/C) was
- 105 defined as positive detection.

#### 106 2.5 Surrogate virus neutralization assay for Wuhan and Omicron variants

- 107 Neutralizing activities against wild type (Euroimmun, Lubeck, Germany) and a cPassTM SARS-
- 108 CoV-2 surrogate virus neutralization test (sVNT) (GenScript Biotech, Piscataway, NJ, USA)
- 109 were used to measure NAb titers against SARS-CoV-2 variants. Recombinant RBD of Omicron;
- 110 BA.2 strains (G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N,
- 111 T478K, E484A, Q493R, Q498R, N501Y, Y505H) and BA.4/5 strains (G339D, S371F, S373P,
- 112 S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V,

113 Q498R, N501Y, Y505H) were incubated in 96-well plates coated with recombinant human

- 114 ACE2 and the sera sample of vaccinees. Samples with a percentage inhibition (% inhibition)
- greater than or equal to 35% threshold for wild type and greater than or equal to 30% for the
- 116 Omicron BA.2 and BA.4/5 subvariants were considered 'seropositive' for SARS-CoV-2
- 117 neutralizing antibodies (Kanokudom et al., 2022a).

#### 118 2.6 Focus reduction neutralization test (FRNT50) against the BA.1 and BA.2 variants

119 Neutralization antibody titers were measured against BA.1 variants (accession number:

120 EPI\_ISL\_8547017) and BA.2 (EPI\_ISL\_11698090) of the SARS-CoV-2 Omicron. The Focus

- 121 reduction neutralization assay was performed as previously described (Assawakosri et al., 2022a,
- 122 2022b). Additionally, the 50% focus reduction was calculated, and the half maximum inhibitory
- 123 concentration (IC50) was determined using PROBIT regression analysis (SPSS Inc., Chicago,
- 124 IL, USA). The detection limit of the assay is 1:20 and NAb values below the detection limit were

125 substituted with a titer of 10.

#### 126 **2.7 Statistical analysis**

127 All statistical analyses were performed using the Statistical Package for the Social Sciences

- 128 (SPSS) v.22.0 (SPSS Inc., Chicago, IL, USA). Figures were generated using GraphPad Prism
- 129 v9.0 (GraphPad Software, San Diego, CA, USA). The categorical data comparison, including sex
- 130 and comorbidities, was performed using Pearson's chi-square test. Total RBD Ig, anti-RBD IgG,
- and NAb levels were reported as geometric mean titers (GMT) with a 95% confidence interval
- 132 (CI). The geometric mean ratio of immunogenicity between day 90–120 and day 28 timepoints
- 133 (GMR D90–120/28) was calculated using the GMT logarithmically transformed and was
- 134 performed using a paired t test. Analysis of variance (ANOVA) with Bonferroni adjustment or
- 135 Kruskal–Wallis H test (for nonparametric data) was used to compare independent groups. The

136	percentage inhibition of the surrogate neutralization assay and anti-nucleocapsid (N) IgG was
137	calculated as the median with the interquartile range (IQR). A <i>P</i> -value of <0.05 (*), <0.01 (**),
138	<0.001 (***) was considered statistically significant.

#### 139 **3. RESULTS**

# 140 **3.1 Demographic data**

141 Of the 334 participants vaccinated with a different COVID-19 booster doses from two previous

142 studies between September and November 2021, 187 participants were included in this long-

143 term follow-up study with assessments on day 90 to 120. The demographic characteristics of this

144 study are presented in Table 1. All participants were healthy Thai adults (well-control

145 comorbidities were acceptable) between 20 and 69 years of age. The mean age (range) of

146 participants was 40.8 (20–69), 43.7 (31–64), 45.0 (20–62), 40.8 (22–55), 40.6 (20–63), 36.7 (21–

147 57), and 40.5 (20–69) for BBIBP, AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273

148 (full- or half-dose), respectively. The average interval between the second and booster doses was

149 160.7 (115–237) days. The baseline sex and comorbidities of the participants were comparable

among all groups. Whereas the mean age of the mRNA-1273 group was significantly lower than

151 other groups. Age was used for statistical adjustment. During the cohort period, two participants

were excluded from the study due to anti-N IgG seroconversion on day 90 to 120 were suspected

153 of COVID-19 infection.

#### 154 3.2 Measurement of Total RBD Ig, Anti-RBD IgG, and Anti-N IgG

155 Overall, after booster dose vaccination, there was a significant reduction in antibody levels, both

total RBD Ig and anti-RBD IgG, on day 90 to 120. At 28 days after booster vaccination, the

157 GMT of the total RBD Ig were 1231, 10,766, 21,240, 22,345, 36,845, and 28,087 U/mL for

158 BBIBP, AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273 (full- or half-dose),

159	respectively. Subsequently, the GMT of the total RBD Ig of six groups were decreased to 620,
160	3984, 5514, 9722, 10,853, and 10,587 U/mL, respectively, at 90-120 days after booster dose.
161	Among the six groups, the decay rate of total RBD Ig levels in the BBIBP group was lower than
162	that in other groups, with a GMR D90–120/28 ratio of 0.50 (95%CI: 0.41–0.61). While the GMR
163	D90–120/28 ratios were comparable in the mRNA booster groups with 0.26 (95%CI: 0.22–0.30)
164	for BNT162b2 and 0.30 (95%CI: 0.27–0.32) for the mRNA-1273 group. Interestingly, a
165	comparable decay rate was evident between half-dose and full-dose mRNA-1273. Similar trends
166	were observed in anti-RBD IgG levels. The percentage reduction of each booster vaccine
167	ranged from 50% to 75%, as shown in Table 2. In summary, individuals boosted with mRNA-
168	1273 possessed the highest persistence of total RBD Ig and anti-RBD IgG among all booster
169	groups, followed by half-dose mRNA-1273, half-dose BNT162b2, BNT162b2, AZD1222, and
170	BBIBP, respectively.
171	3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2,
171 172	3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5
171 172 173	<ul><li>3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5</li><li>A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate</li></ul>
171 172 173 174	<b>3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2,</b> and BA.4/5A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogateneutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.
171 172 173 174 175	<b>3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2,and BA.4/5</b> A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogateneutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.Most participants (85 to 100%) who had received the viral vector or the mRNA booster were
<ol> <li>171</li> <li>172</li> <li>173</li> <li>174</li> <li>175</li> <li>176</li> </ol>	3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2,and BA.4/5A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogateneutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.Most participants (85 to 100%) who had received the viral vector or the mRNA booster wereseropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In
<ol> <li>171</li> <li>172</li> <li>173</li> <li>174</li> <li>175</li> <li>176</li> <li>177</li> </ol>	3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5 A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate neutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants. Most participants (85 to 100%) who had received the viral vector or the mRNA booster were seropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In contrast, only 61% and 20% to 40% of participants who received BBIBP booster presented
<ol> <li>171</li> <li>172</li> <li>173</li> <li>174</li> <li>175</li> <li>176</li> <li>177</li> <li>178</li> </ol>	3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5 A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate neutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants. Most participants (85 to 100%) who had received the viral vector or the mRNA booster were seropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In contrast, only 61% and 20% to 40% of participants who received BBIBP booster presented seropositivity for wild type and Omicron BA.2 or BA.4/5 subvariants, respectively
<ol> <li>171</li> <li>172</li> <li>173</li> <li>174</li> <li>175</li> <li>176</li> <li>177</li> <li>178</li> <li>179</li> </ol>	<ul> <li>3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5</li> <li>A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate neutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.</li> <li>Most participants (85 to 100%) who had received the viral vector or the mRNA booster were seropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In contrast, only 61% and 20% to 40% of participants who received BBIBP booster presented seropositivity for wild type and Omicron BA.2 or BA.4/5 subvariants, respectively</li> <li>(Supplementary Table1). The median %inhibition of NAbs against the wild type remained higher</li> </ul>
<ol> <li>171</li> <li>172</li> <li>173</li> <li>174</li> <li>175</li> <li>176</li> <li>177</li> <li>178</li> <li>179</li> <li>180</li> </ol>	<ul> <li>3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5</li> <li>A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate neutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.</li> <li>Most participants (85 to 100%) who had received the viral vector or the mRNA booster were seropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In contrast, only 61% and 20% to 40% of participants who received BBIBP booster presented seropositivity for wild type and Omicron BA.2 or BA.4/5 subvariants, respectively</li> <li>(Supplementary Table1). The median %inhibition of NAbs against the wild type remained higher than 95% for the viral vector and mRNA booster groups (Figure 2A). However, the median</li> </ul>
<ol> <li>171</li> <li>172</li> <li>173</li> <li>174</li> <li>175</li> <li>176</li> <li>177</li> <li>178</li> <li>179</li> <li>180</li> <li>181</li> </ol>	<ul> <li>3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2, and BA.4/5</li> <li>A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate neutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.</li> <li>Most participants (85 to 100%) who had received the viral vector or the mRNA booster were seropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In contrast, only 61% and 20% to 40% of participants who received BBIBP booster presented seropositivity for wild type and Omicron BA.2 or BA.4/5 subvariants, respectively</li> <li>(Supplementary Table1). The median %inhibition of NAbs against the wild type remained higher than 95% for the viral vector and mRNA booster groups (Figure 2A). However, the median %inhibition of NAbs against at 26.8% in</li> </ul>

## 182 BBIBP, 60.3% in AZD1222, 60.0% in BNT162b2, and 77.7% in the half-dose BNT162b2,

- 183 75.4% in mRNA-1273, and 82.9% in the half-dose mRNA-1273 group (Figure 2B). Moreover, a
- reduction of %inhibition was also observed against the BA.4/5 subvariants with 15.6%, 50.2%,
- 45.6%, 80.5%, 67.5%, and 79.6% in the six groups, respectively (Figure 2C). In summary, the
- 186 median %inhibition of neutralizing activity against the Omicron variants BA.2 and BA.5, was
- 187 lower than that observed against the wild type variant. While the median %inhibition of
- neutralizing activity against the BA.5 was 5% to 15% lower compared to that against the BA.2
- 189 subvariant among all booster groups.

## 190 **3.4 Focus reduction neutralization test against the BA.1 and BA.2 variants**

191 A subset of 20 samples from the AZD1222, BNT162b2, and mRNA-1273 groups on day 28 and 192 day 90 to 120 was determined in the live virus focus reduction neutralization test (the BBIBP and 193 the half-dose group were not included). Most of the participants (95% to 100%) on heterologous 194 mRNA and viral vector booster schedules showed detectable NAbs on day 90 to 120. Previously, 195 NAb GMTs against BA.1 were 243 for AZD1222, 313 for BNT162b2, and 645 for the mRNA-196 1273 groups at 28 days after the booster dose (Assawakosri et al., 2022b). Subsequently, the 197 GMT of NAbs against BA.1 significantly decreased to 60.1, 82.6, and 133 in the three groups, 198 respectively (Figure 3). While the NAbs GMTs against BA.2 were 340, 449, and 1035 in each 199 group, which significantly dropped to 76.5, 70.5, and 229 in the AZD1222, BNT161b2 and 200 mRNA-1273 groups, respectively. In comparison, the GMR D90-120/28 ratio of NAbs against 201 BA.1 was approximately equal to the GMR D90–120/28 ratio of NAbs against BA.2. The 202 percentage reduction among the three vaccines ranged between 70% and 85%, as shown in 203 Supplementary Table 2. In accordance with those binding antibody levels, this finding

demonstrated that the neutralizing antibody significantly decreased on day 90 to 120 comparedto day 28 after the booster dose.

#### **4. Discussion**

207 In this study, we determined the persistence levels of binding antibodies and NAbs against the 208 RBD of SARS-CoV-2 on day 90 to 120 after implementing COVID-19 booster dose vaccines 209 that included BBIBP, AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273 (full- or half-210 dose) in individuals primed with two doses of CoronaVac. Our findings revealed that boosting 211 with the heterologous vaccine elicited high levels of total RBD Ig, anti-RBD IgG, and NAbs at 212 28 days following booster vaccination. However, the antibody response substantially waned 213 within three to four months after the booster dose, with a different pattern between each booster 214 vaccine platforms. Additionally, consistent with the previous study in the United Kingdom, anti-215 spike IgG significantly decreased on day 84 after booster dose in participants who had previously 216 been vaccinated with two doses of AZD1222 (Liu et al., 2022). 217 Total RBD Ig and anti-RBD IgG levels among all heterologous mRNA and viral vector booster 218 vaccines highly remained on day 90 to 120 after vaccination. Conversely, binding antibody 219 levels were lower in the BBIBP booster group. Among them, mRNA-1273 (full- and half-dose) 220 demonstrated the highest level of total RBD Ig and anti-RBD IgG, while the decay rate of the 221 mRNA-1273 booster was faster than that of the AZD1222 and BBIBP booster. Moreover, the 222 decay rate of the binding antibodies was comparable between the full-dose and half-dose

223 mRNA-1273 boosters. In agreement with the previous study of participants vaccinated with two

doses of mRNA-1273 plus mRNA-1273 booster, the half-dose mRNA-1273 booster provided an

antibody response similar to that of the full-dose booster (Choi et al., 2021). These results

suggest that the half-dose mRNA-1273 is interchangeable with the full-dose mRNA-1273 withno difference in decay rate.

228	Several studies have demonstrated that neutralizing antibody level is correlated with vaccine-
229	induced immune protection against SARS-CoV-2 symptomatic disease (Earle et al., 2021;
230	Favresse et al., 2022; Khoury et al., 2021; Koch et al., 2021). Therefore, a higher level of NAb
231	may represent a higher percentage of vaccine efficacy against severe infection. After 90 to 120
232	days post-vaccinated, we observed a high seropositive rate of NAb against the Omicron variant
233	among participants who received heterologous mRNA and viral vector booster vaccines,
234	especially mRNA-1273 vaccines. In line with a study in China that evaluated the use of the
235	mRNA RQ3013 vaccine as the booster dose, mRNA booster provided the highest neutralizing
236	antibodies against the omicron variant compared to other COVID-19 platforms (Zhang et al.,
237	2022). In addition, we observed a comparable level of neutralizing antibodies against the BA.1
238	and the BA.2 subvariants. In accordance with those observed in the previous study, the
239	neutralizing antibody titers against the BA.2 subvariant were approximately equal to the BA.1
240	subvariant and 1.7 times higher in participants with a homologous BNT162b2 booster (Chen et
241	al., 2022; Kurhade et al., 2022).

The booster consisting of a heterologous mRNA and viral vector vaccine showed a higher
seropositivity rate of neutralizing activity against BA.4/5, while the BBIBP booster achieved
only 20% seropositivity. Similar to the study of three-dose CoronaVac and two-dose CoronaVac
plus BNT162b2, the seropositive number of Plaque neutralizing antibody (PRNT50) against
BA.4 and BA.5 was only 10% in homologous three-dose CoronaVac compared to 90–100% in a
heterologous booster (Cheng et al., 2022). The results showed that the NAbs induced by
heterologous mRNA and viral vector as a third dose vaccination had broad neutralizing activity

249	against several subvariants of SARS-CoV-2. Consistent with a previous study, after the
250	homologous mRNA booster, the percentage of somatic hypermutated memory B cells increased
251	and indicated B cell affinity maturation (Paschold et al., 2022). In comparison, the median
252	%inhibition of neutralizing activity against Omicron BA.2 and BA.4/5 showed a significantly
253	lower susceptibility than against wild type. Whereas the median %inhibition of neutralizing
254	activity against BA.4/5 also demonstrated a lower trend than that of BA.2. Consistent with the
255	50% neutralization titers against BA.4/5 data from homologous mRNA booster, BA.4/5 had
256	lower neutralizing antibody titers than the BA.2.12.1 and D614G variants (Qu et al., 2022).
257	These results indicated that the BA.4/5 subvariant exerts a higher vaccine-induced immune
258	evasion and BA.4/5 certainly has overtaken other circulating subvariants.
259	Our findings showed that NAbs titers against the Omicron subvariant induced by the third dose
260	booster waned over time, despite the fact that most participants had detectable NAbs on day 90
261	to 120 after the booster dose. According to real-world VE data from Brazil, the estimated VE
262	against symptomatic infection by the Omicron variant in participants who received a primary
263	series of CoronaVac plus the BNT162b2 booster significantly decreased from 63.6% at day 14-
264	30 to 1.7% at day 120 or more after the booster dose (Cerqueira-Silva et al., 2022a). Another
265	study showed a decrease in VE from 57.3% at day 8–59 to 15.7% at day ≥120 after BNT162b2
266	booster, while the VE in the homologous CoronaVac booster was only 8.1% at day 8–59 and
267	decreased to -24.8% at day $\geq$ 120 post-boosted (Ranzani et al., 2022). However, the estimated VE
268	against hospitalization and death remained highly effective, with 84.1% at day 120 or more after
269	the booster dose. These results suggested that the third dose mRNA vaccine still achieved
270	protection against severe disease, although it showed less protection against infection. However,

individuals with inactivated boosters may require additional booster doses with other vaccineplatforms due to inadequate serological immune response and protection.

Our study has several limitations. First, due to the extension of the present study from the previous study cohort, almost 44% of all participants were lost to follow-up during the extended period at four-month follow-up timepoint. Second, the surrogate virus neutralization assay technique reached the upper detection limit for the wild type. Therefore, this method could not determine the exact NAb level. Lastly, data on the cellular immunity profile was not investigated. Data on the live virus neutralization test against other newly emerged BA.4/5 or

279 BA.2.75 will be of great interest for further exploration.

# 280 **5.** Conclusion

At 90 to 120 days after third dose vaccination with the viral vector and mRNA in CoronaVac-

282 primed individuals demonstrated high detectable rate of humoral immune responses both

283 binding, and neutralizing antibodies against emerging Omicron BA.1, BA.2 and BA.4/5 SARS-

284 CoV-2 subvariants. Nonetheless, real-world data has demonstrated a low percentage of VE

against COVID-19 infection for individuals receiving any types of booster doses. To maintain

the immune response against COVID-19 infection, a fourth booster dose is recommended for all

287 groups, especially those who received the inactivated vaccine as the third dose booster.

# 288 **Declaration**

#### 289 Author contribution statement

- 290 Suvichada Assawakosri: Conceived and designed the experiments; Performed the experiments;
- Analyzed and interpreted the data; Wrote the paper.
- 292 Sitthichai Kanokudom, Nungruthai Suntronwong, Jira Chansaenroj: Performed the experiments;
- Analyzed and interpreted the data.
- 294 Chompoonut Auphimai, Pornjarim Nilyanimit, Preeyaporn Vichaiwattana, Thanunrat
- 295 Thongmee, Thaneeya Duangchinda, Warangkana Chantima, Pattarakul Pakchotanon Donchida
- 296 Srimuan, Thaksaporn Thatsanatorn, Sirapa Klinfueng: Performed the experiments.
- 297 Natthinee Sudhinaraset, Nasamon Wanlapakorn, Juthathip Mongkolsapaya, Sittisak Honsawek,
- 298 Yong Poovorawan: Conceived and designed the experiments; Contributed reagents, materials,
- analysis tools or data.

### **Declaration of interests statement**

301 The authors declare that they have no conflict of interest.

#### 302 Funding Statement

- 303 This work was supported by the Health Systems Research Institute (HSRI), the National
- 304 Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology,
- 305 Chulalongkorn University and King Chulalongkorn Memorial Hospital and was supported by the
- 306 Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported
- 307 by the National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No.
- 308 P2051613).

# 309 Acknowledgments

- 310 The authors are grateful to the Center of Excellence in Clinical Virology staffs, all participants,
- 311 BJC Big C Foundation and MK restaurant group public Co., Ltd. for helping and supporting this
- 312 project. We also thank the Ministry of Public Health, the Chulabhorn Royal Academy, and
- 313 Zullig pharma for providing the vaccines for this study.

# **References**

315	Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, et al.
316	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous
317	and heterologous COVID-19 booster vaccines in healthy adults after a two-dose
318	AZD1222 vaccination. Int J Infect Dis 2022a; 122:793-801.
319	Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
320	al. Neutralizing activities against the Omicron variant after a heterologous booster in
321	healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis 2022b;
322	226:1372-1381.
323	Centers for Disease Control and Prevention, Interim Clinical Considerations for Use of COVID-
324	19 Vaccines Currently Approved or Authorized in the United States-Centers for Disease
325	Control and Prevention. https://www.cdc.gov/vaccines/covid-19/clinical-
326	considerations/interim-considerations-us.html#booster-dose. (Accessed 26 August 2022).
327	Cerqueira-Silva T, De Araujo Oliveira V, Paixão ES, Júnior JB, Penna GO, Werneck GL, et al.
328	Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the
329	Omicron period in Brazil. Nat Commun 2022a;13:4154.
330	Cerqueira-Silva T, Katikireddi SV, De Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES,
331	et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat
332	Med 2022b; 28:838–43.
333	Chen L-L, Chu AW-H, Zhang RR-Q, Hung IF-N, To KK-W. Serum neutralisation of the SARS-
334	CoV-2 omicron sublineage BA.2. Lancet Microbe 2022;3:e404.

335	Cheng SS, Mok CK, Li JK, Ng SS, Lam BH, Jeevan T, et al. Plaque-neutralizing antibody to
336	BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac
337	vaccines, natural infection, and breakthrough infection. J Clin Virol 2022;156:105273.
338	Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-
339	2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med 2021;
340	27:2025–31.
341	Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence
342	for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021; 39:4423-8.
343	Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, et al. mRNA-1273 and
344	BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2
345	omicron variant. Cell Rep Med 2022; 33:100529.
346	Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, et al. Vaccine-induced binding
347	and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2
348	booster. J Med Virol 2022. doi: 10.1002/jmv.28164.
349	Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
350	al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and
351	mRNA COVID-19 Vaccines in fully immunized healthy adults with inactivated vaccine.
352	Vaccines 2022a; 10:86.
353	Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.
354	Comparison of the reactogenicity and immunogenicity of a reduced and standard booster
355	dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated
356	vaccine. Vaccine 2022b; 40:5657–63.

357	Khoury DS.	Cromer D	Revnaldi A	. Schlub TE.	Wheatley	AK. Juno JA	. et al. Neutraliz	zing
221	I I I D D I D D D		1 I CO I HUIGH I I		, i i noutro j			~

- 358 antibody levels are highly predictive of immune protection from symptomatic SARS-
- 359 CoV-2 infection. Nat Med 2021;27:1205–11.
- 360 Kimura I, Yamasoba D, Tamura T, Nao N, Oda Y, Mitoma S, et al. Virological characteristics of
- the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5. Cold
  Spring Harbor Laboratory; 2022.
- Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of vaccine-induced
   protection against SARS-CoV-2. Vaccines 2021;9:238.
- Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARSCoV-2: A comparative computational study of spike protein. J Med Virol 2022;94:16411649.
- 368 Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, et al. Neutralization of Omicron BA.1,
- 369 BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun
  370 2022;13:3602.
- 371 Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of immunogenicity
- after seven COVID-19 vaccines given as third dose boosters following two doses of
- 373 ChAdOx1 nCov-19 or BNT162b2 in the UK: Three-month analyses of the COV-BOOST
  374 trial. J Infect 2022; 84:795–813.
- Lu L, Mok BWY, Chen LL, Chan JMC, Tsang OTY, Lam BHS, et al. Neutralization of Severe
   Acute Respiratory Syndrome Coronavirus 2 Omicron variant by sera from BNT162b2 or
   CoronaVac vaccine recipients. Clin Infect Dis 2022;75:e822–e6.

378	Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-
379	CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science
380	2022;375:678–80.
381	Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, et al. Rapid
382	Hypermutation B cell trajectory recruits previously primed B Cells Upon Third SARS-
383	Cov-2 mRNA Vaccination. Front Immunol 2022;13:876306.
384	Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al.
385	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature
386	2022;602:671–5.
387	Qu P, Faraone JN, Evans JP, Zheng Y-M, Yu L, Ma Q, et al. Durability of booster mRNA
388	vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants. New Engl J Med
389	2022;387:1329–31.
390	Ranzani OT, Hitchings MDT, De Melo RL, De França GVA, Fernandes CDFR, Lind ML, et al.
391	Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous
392	boosters against Omicron in Brazil. Nat Commun 2022; 13:5536.
393	Sinovac: CoronaVac–COVID19 Vaccine Tracker. Available from:
394	https://covid19.trackvaccines.org/vaccines/7/. (Accessed 05 October 2022).
395	Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Continued
396	emergence, and evolution of Omicron in South Africa: New BA.4 and BA.5 lineages.
397	medRxiv [Preprint] 2022. https://doi.org/10.1101/2022.05.01.22274406

398	Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic
399	expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature
400	2022;603:679–86.
401	Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological characteristics of
402	the SARS-CoV-2 Omicron BA.2 spike. Cell 2022; 185:2103–15.e19.
403	Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z, et al. Immunogenicity, durability, and safety of

- 404 an mRNA and three platform-based COVID-19 vaccines as a third dose following two
- 405 doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase
- 406 2 trial. eClinicalMedicine 2022;54:101680.
- 407 Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and
- 408 vaccine effectivity. J Med Virol 2022.

# 409 Figure captions and Tables

410



#### 411 **Figure 1. Diagram of recruited participants and study groups.** In our previous study, 334

412 participants who had completed two injections of CoronaVac were enrolled and received a single

413 booster dose of including BBIBP (n=57), AZD1222 (n=55), BNT162b2 (n=54), half-dose

414 BNT162b2 (n=59), mRNA-1273 (n=58), or half-dose mRNA-1273 (n=51) at Day 28 after

- 415 booster timepoint. This extended study, a total of 187 matched individuals including those
- 416 receiving BBIBP (n=24), AZD1222 (n=28), BNT162b2 (n=25), half-dose BNT162b2 (n=37),
- 417 mRNA-1273 (n=39), or half-dose mRNA-1273 (n=34) who completed day 90 to 120 follow up
- 418 timepoints were eligible for final analysis of binding and neutralizing antibodies.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.24.22282735; this version posted November 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



419 Figure 2: Neutralizing activities against wild type, Omicron BA.2, and BA.4/5 variants at

420 day 90 to 120 post-boosted using a surrogate virus neutralization test. A subset of samples

421 (n=20/group) from BBIBP, AZD1222, BNT162b, half-dose BNT162b2, mRNA-1273, and half-

422 dose mRNA-1273 groups was randomly selected to test for sVNT. (A) Neutralizing activities

423 against the SARS-CoV-2 wild type are shown as %inhibition and (B) Neutralizing activities

424 against the SARS-CoV-2 Omicron variant (BA.2) are shown as %inhibition (C) Neutralizing

425 activities against the SARS-CoV-2 Omicron variant (BA.4/5) are shown as %inhibition. Median

426 values with interquartile ranges (IQRs) are denoted as horizontal bars. The dotted lines designate

427 cutoff values at 35% for wild type and 30% for Omicron BA.2 and BA.5 subvariants.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.24.22282735; this version posted November 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





430 Figure 3. Comparison of neutralizing antibody titers against Omicron BA.1 and BA.2

431 **between day 28 and day 90 to 120 after booster vaccination.** A subset of samples

432 (n=20/group) from AZD1222, BNT162b, and mRNA-1273 groups was randomly selected for

433 testing of the focus reduction neutralization test (FRNT50) against SARS-CoV-2 Omicron

434 BA.1 and BA.2 subvariant. Each data point represents an individual who received a booster

435 vaccine, including the viral vector vaccine, AZD1222 (orange), the mRNA vaccine,

436 BNT162b2 (yellow), or mRNA-1273 (blue). The error bars present GMT. Values below the

437 limit were substituted with a titer of 10. The dotted lines designate cutoff values at 1:20.

	Total	BBIBP	AZD1222	BNT162b2	Half BNT162b2	mRNA-1273	Half mRNA-1273
Total number (n)	187	24	28	25	37	39	34
Mean age (range) year	40.9 (20-69)	43.7 (31-64)	45.0 (20-62)	40.8 (22-55)	40.6 (20-63)	37.0 (21-57)	40.6 (20-69)
Sex							
Male (%)	88/187	12/24	10/28	17/25	16/37	18/39	15/34
	(47.1%)	(50.0%)	(35.7%)	(68.0%)	(43.2%)	(46.2%)	(44.1%)
Female (%)	99/187	12/24	18/28	8/25	21/37	21/39	19/34
	(52.9%)	(50.0%)	(64.3%)	(32.0%)	(56.8%)	(53.8%)	(55.9%)
Underlying disease (%)							
Allergy	12/187 (6.4%)	1/24 (4.2%)	2/28 (7.1%)	1/25 (4.0%)	2/37 (5.4%)	3/39 (7.7%)	3/34 (8.8%)
Cardiovascular	3/187 (1.6%)	1/24 (4.2%)	2/28 (7.1%)	-	-	-	-
diseases	10/187 (5.3%)	1/24 (4.2%)	4/28 (14.3%)	2/25 (8.0%)	2/37 (5.4%)	1/39 (2.6%)	-
<b>Diabetes Mellitus</b>	3/187 (1.6%)	1/24 (4.2%)	1/28 (3.6%)	1/25 (4.0%)	-	-	-
Dyslipidemia	15/187 (8.0%)	1/24 (4.2%)	3/28 (10.7%)	2/25 (8.0%)	4/37 (10.8%)	3/39 (7.7%)	2/34 (5.9%)
Hypertension	3/187 (1.6%)	1/24 (4.2%)	-	-	-	1/39 (2.6%)	1/34 (2.9%)
Thyroid	10/187 (5.3%)	2/24 (8.3%)	1/28 (3.6%)	-	2/37 (5.4%)	2/39(5.1%)	3/34 (8.8%)
Other (Gout, Asthma,							
COPD, etc.)							
Interval between the 2 <sup>nd</sup> dose	160.6	166.6	153.6	144.2	162.3	168.5	163.5
and the booster dose	(115-237)	(115-197)	(130-191)	(120-166)	(148-213)	(148-237)	(150-210)
Follow-up							
Third visit							
Mean (range) day	28.2	29.0	27.9	28.1	28.3	27.7	28.6
	(22-36)	(25-35)	(22-29)	(28-30)	(27-30)	(27-32)	(28-36)
Fourth visit							
Mean (range) day	100.1	93.3	120	120.6	92.8	91.5	91.3
	(86-127)	(89-113)	(117-121)	(119-127)	(90-106)	(89-102)	(86-95)

439	9 <b>Table 1.</b> Demographics and baseline characteristics	of the enrolled participants.
-----	---	-------------------------------

# **Table 2.** Measurement of GMTs and GMRs (with 95% confidence intervals) of total RBD Ig (U/mL) and anti-RBD IgG (BAU/mL)

	BBIBP	AZD1222	<b>BNT162b2</b> (II)	Half BNT162b2	mRNA-1273	Half-dose mRNA-1273
	(n=24)	( <b>n=28</b> )	(n=25)	( <b>n=37</b> )	( <b>n=39</b> )	(n=34)
SARS-CoV-2 total RBD Ig, (U/	mL), GMT (95% CI)	)				
Day 28	1231 (891-1699)	10766 (8235-14074)	21240 (16478-27378)	22345 (18596-26850)	36845 (29827-45513)	28087 (24041-32813)
Day 90	620 (425-904)	3984 (3047-5209)	5514 (4045-7517)	9722 (7937-11909)	10853 (8861-13292)	10587 (8724-12848)
Day 90–120/28 ratio (GMR)	0.50 (0.41-0.61)	0.39 (0.33-0.45)	0.26 (0.22-0.30)	0.44 (0.39-0.49)	0.30 (0.27-0.32)	0.38 (0.34-0.42)
<i>P</i> -value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	<0.001
(Between D28 and D90–120)						
%Reduction	50.4%	70.0%	74.0%	56.5%	69.8%	62.0%
SARS-CoV-2 anti-RBD IgG, (I	BAU/mL), GMT (95%	% CI)				
Day 28	175 (127-241)	1618 (1256-2082)	3708 (2984-4607)	4351 (3682-5141)	7264 (6056-8714)	5636 (4783-6641)
Day 90	84.9 (59.4-121)	623 (481-808)	917 (690-1219)	1743 (1405-2162)	1942 (1594-2365)	1985 (1602-2459)
Day 90-120/28 ratio (GMR)	0.49 (0.43-0.55)	0.39 (0.32-0.45)	0.25 (0.21-0.29)	0.40 (0.36-0.45)	0.27 (0.24-0.31)	0.35 (0.31-0.40)
<i>P</i> -value	< 0.001	<0.001	< 0.001	< 0.001	<0.001	< 0.001
(Between D28 and D90–120)						
%Reduction	51.5%	61.5%	75.3%	59.9%	73.3%	64.8%

442 compared between day 28, and day 90–120 in each vaccine regimen.